Cargando…
Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease
Oncogene addiction in non-small-cell lung cancer (NSCLC) has profound diagnostic and therapeutic implications. ALK, ROS1 and NTRK rearrangements are found in about 2–7%, 1–2% and 0.2% of unselected NSCLC samples, respectively; however, their frequency is markedly higher in younger and never-smoker p...
Autores principales: | Marinelli, Daniele, Siringo, Marco, Metro, Giulio, Ricciuti, Biagio, Gelibter, Alain J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioExcel Publishing Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576009/ https://www.ncbi.nlm.nih.gov/pubmed/36303600 http://dx.doi.org/10.7573/dic.2022-3-1 |
Ejemplares similares
-
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease
por: Metro, Giulio, et al.
Publicado: (2022) -
Evaluation of Efficacy of ALK Inhibitors According to Body Mass Index in ALK Rearranged NSCLC Patients—A Retrospective Observational Study
por: Siringo, Marco, et al.
Publicado: (2023) -
Non-small-cell lung cancer: how to manage RET-positive disease
por: Andrini, Elisa, et al.
Publicado: (2022) -
Advanced non-small-cell lung cancer: how to manage non-oncogene disease
por: De Giglio, Andrea, et al.
Publicado: (2022) -
Non-small-cell lung cancer: how to manage EGFR-mutated disease
por: Pecci, Federica, et al.
Publicado: (2022)